Theta Neurotech

Why we invested

MARK'S STATED LOGIC Primarily a founder bet. Mark found the founder super competent, felt he deeply understood the mission, and saw a genuine, personal connection to it. We backed the person and their fit to the problem above all else — the classic seed-stage call where the team is the asset and everything else is still an option.

• VERIFIED Credentialed origin: UChicago / Polsky New Venture Challenge, with UChicago Medicine as a clinical partner — the founder is embedded in the right research ecosystem for this problem.
• CLAIMED Real algorithm signal early: retrospective validation reported ~89% sensitivity with a ~35-minute mean warning window on hospital EEG — suggests the model predicts, not just detects.
• CLAIMED Genuine unmet need: ~3.4M Americans with epilepsy; the unpredictability of seizures is the core safety and quality-of-life problem. A reliable warning window is valuable.
• CLAIMED Non-invasive edge: a behind-the-ear form factor is far less invasive than an implant and more continuous than a wrist device, aiming at all-day real-world wear.
• VERIFIED Cheap, asymmetric entry: seed-stage, ~$3M raised, into a category (seizure forecasting) with no approved consumer-wearable winner yet.

What the company is

CLAIMED Theta builds a wearable EEG system for seizure prediction: two small adhesive sensors worn behind the ears that stream brain signals to a phone, with an on-device model that flags pre-seizure changes and alerts the patient and caregivers roughly 30 to 60 minutes ahead. VERIFIED It is pre-clinical: retrospective algorithm validation is done, and a first-in-human pilot is planned with UChicago Medicine. No prospective human data, no FDA clearance, and no revenue yet. UNVERIFIED Our internal note says founded 2022; every public source says 2024 out of the Polsky venture challenge — worth reconciling.

What we probed in diligence

No DRA data room for this name — these are the honest hard questions a founder bet at this stage has to answer.

1. Retrospective vs prospective. Hospital-EEG accuracy rarely survives contact with a noisier, fewer-channel, ambulatory wearable. Does behind-the-ear EEG capture enough to hold ~89% sensitivity in the real world?
2. Specificity / alarm burden. Sensitivity alone means nothing without the false-positive rate. A device that cries wolf gets taken off. What is specificity, and how many alerts per day?
3. FDA path and timeline. A predictive device likely has no clean 510(k) predicate (De Novo). What class, what pivotal trial size, how many years and dollars to clearance?
4. Reimbursement. No CPT code for consumer seizure forecasting today. Cash-pay wearable or prescription/DME path? It changes the whole model.
5. Competition and durability. Empatica is FDA-cleared but detects convulsive seizures rather than predicting; NeuroPace is an implant. Is a ~35-minute prediction window a defensible moat or leapfroggable?
6. Runway to proof. ~$3M and four people — enough to fund the UChicago pilot and generate the prospective data the next raise needs before cash runs out?

Bull case

• First credible non-invasive wearable that predicts (not just detects) seizures, in a category with no consumer winner.
• Strong retrospective signal plus a named clinical partner de-risks the next data milestone. CLAIMED
• Capital-efficient team out of a top research ecosystem — a small check with large asymmetric upside on a founder we rate highly.

Bear case

• Pre-clinical medical device: no prospective human data, no FDA clearance, no revenue. Binary on the pilot.
• Retrospective hospital-EEG accuracy almost never transfers cleanly to a 2-channel behind-the-ear wearable.
• $3M and four people is thin for a multi-year regulated-device slog; near-certain dilutive raises against hard clinical gates.

Key risks

• Clinical: prospective sensitivity and false-alarm rate underperform the retrospective claims.
• Regulatory: De Novo path, multi-year timeline, uncertain trial cost.
• Commercial: no reimbursement pathway; adoption depends on the alarm burden being tolerable.
• Financing: runway to prospective proof; down-round or stall risk if the pilot slips.